OncLive
OncLive
  • 16 913
  • 8 209 510
Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLC
Jessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion-positive NSCLC.
Jessica Lin, MD, associate professor, medicine, Harvard Medical School; attending physician, Center for Thoracic Cancers, Henri and Belinda Termeer Center for Targeted Therapies, Massachusetts General Hospital, discusses key findings from the phase 2 TRUST-I trial (NCT04395677) of taletrectinib (AB-106) in patients with ROS1 fusion-positive non-small cell lung cancer (NSCLC).
TRUST-I, which was conducted in China, evaluated the next-generation ROS1 inhibitor in patients with metastatic ROS1 fusion-positive NSCLC. Currently, 2 first-generation ROS1 inhibitors are FDA approved: crizotinib (Xalkori) and entrectinib (Rozlytrek). Both agents induce median progression-free survival (PFS) outcomes ranging from approximately 16 to 19 months, Lin says. Additionally, the next-generation ROS1 and TRK inhibitor repotrectinib (Augtyro) was approved by the FDA in 2023 for patients with locally advanced or metastatic ROS1-positive NSCLC. In the pivotal phase 1/2 TRIDENT-1 trial (NCT03093116), repotrectinib elicited a median PFS of 35.7 months (95% CI, 27.4-not estimable) in patients who had not previously received a ROS1 TKI.
At the 2024 ASCO Annual Meeting, results from TRUST-I were presented from both the TKI-naive (n = 106) and crizotinib-pretreated (n = 67) patient populations. In the TKI-naive population, taletrectinib generated a confirmed overall response rate (cORR) of 90.6% (95% CI, 83.33%-95.38%), and the median PFS was not reached (NR; 95% CI, 29.1-NR) after a median follow-up of 23.5 months. In crizotinib-pretreated patients, the cORR was 51.5% (95% CI, 38.88%-64.01%), and the median PFS was 7.6 months (95% CI, 5.5-12.0) at a median follow-up of 9.7 months. These findings support the use of taletrectinib as an effective therapy for patients with ROS1 fusion-positive NSCLC who have received prior ROS1 inhibitors. Currently, repotrectinib is the only FDA approved agent for such cases, and additional therapies are needed for this patient population, Lin emphasizes.
Taletrectinib also has central nervous system activity. In TRUST-I, the intracranial cORRs were 87.5% (95% CI, 47.35%-99.68%) and 73.3% (95% CI, 44.90%-92.21%) in patients with baseline brain metastases who were TKI naive (n = 8) and crizotinib pretreated (n = 15), respectively.
The safety profile of taletrectinib is also noteworthy, Lin explains. Entrectinib and repotrectinib, which inhibit both ROS1 and TRK proteins, can accordingly cause neurologic adverse effects (AEs) due to TRK inhibition. In TRUST-I, however, taletrectinib was associated with few neurologic AEs, Lin notes. Although dizziness was observed in the trial, most treatment-related AEs were related to increases in aspartate aminotransferase/alanine aminotransferase levels and gastrointestinal AEs, indicating that taletrectinib may have a more favorable safety profile vs other agents in its class, according to Lin.
See our site for more information about TRUST-I: www.onclive.com/view/taletrectinib-yields-durable-responses-in-tki-naive-and-crizotinib-pretreated-ros1-nsclc
Website: www.onclive.com
Twitter: OncLive
Facebook: OncLive/
LinkedIn: www.linkedin.com/company/onclive
Переглядів: 38

Відео

Dr Cherng on Considerations for the Use of Bispecific Antibodies in DLBCL
Переглядів 637 годин тому
Hua-Jay “Jeff” Cherng, MD, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with DLBCL. Hua-Jay “Jeff” Cherng, MD, assistant professor, medicine, Lymphoma Program, Division of Hematology and Oncology, Columbia University Irving Medical Center, discusses efficacy and safety considerations for the use of bispecific antibodies in patients with non-Hodgk...
Dr Tarantino on the Safety of T-DXd and T-DM1 in HER2+ Breast Cancer
Переглядів 247 годин тому
Paolo Tarantino, MD, discusses updated safety data from the phase 3 DESTINY-Breast03 trial of T-DXd in HER2 breast cancer. Paolo Tarantino, MD, researcher, the European Institute of Oncology, clinical research fellow, Dana-Farber Cancer Institute, discusses the safety profiles of fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) and ado-trastuzumab emtansine (Kadcyla; T-DM1) when used in metasta...
Dr Khushalani on Fixed-Dose Treatment Regimens in Advanced Melanoma
Переглядів 1067 годин тому
Nikhil Khushalani, MD, discusses the benefits and limitations of fixed-dose treatment regimens in patients with unresectable or metastatic melanoma. Nikhil Khushalani, MD, vice chair, Department of Cutaneous Oncology, Moffitt Cancer Center, discusses the benefits and limitations of fixed-dose treatment regimens, such as the combination of fianlimab (formerly REGN 3767) and cemiplimab-rwlc (Libt...
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
Переглядів 297 годин тому
Bradley McGregor, MD, discusses the investigation of sacituzumab govitecan plus enfortumab vedotin in metastatic urothelial cancer. Bradley McGregor, MD, senior physician, clinical director, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the rationale for conducting the phase 1 Double Antibody-Drug Conjugate (D...
Information Overload in Oncology: Episode 2
Переглядів 907 годин тому
Website: www.onclive.com Twitter: OncLive Facebook: OncLive/ LinkedIn: www.linkedin.com/company/onclive
Dr Hunter on the Evolution of Pathology in Myelofibrosis
Переглядів 227 годин тому
Anthony M. Hunter, MD, assistant professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, medical director, Immediate Care Center, Winship Cancer Institute of Emory University, discusses the evolution of pathology in myelofibrosis based on outcomes from ongoing clinical trials. Website: www.onclive.com Twitter: OncLive Facebook: Onc...
Dr Garcia-Manero on the Impact of Luspatercept on Hematopoietic Lineages in Lower-Risk MDS
Переглядів 399 годин тому
Guillermo Garcia-Manero, MD, discusses the safety and impact of luspatercept on hematopoetic lineages in transfusion-dependent lower-risk MDS. Guillermo Garcia-Manero, MD, professor, chief, Section of Myelodysplastic Syndromes, chair, Translational Research, fellowship program director, Department of Leukemia, Division of Cancer Medicine, chair, faculty senate, The University of Texas MD Anders...
Dr Davar on the Initial Safety of DSP-5336 in Relapsed/Refractory Acute Leukemia
Переглядів 389 годин тому
Naval G. Davar, MD, professor, director, Leukemia Research Alliance Program, Department of Leukemia, Division of Cancer Medicine, The University of MD Anderson Cancer Center, discusses updated findings from a phase 1/2 study (NCT04988555) of the investigational menin-MLL inhibitor DSP-5336 in relapsed/refractory acute leukemias. DSP-5336 is an oral small molecule designed to inhibit the interac...
Dr Mouabbi on the Use of Ribociclib vs Abemaciclib in HR+/HER2- Breast Cancer
Переглядів 3812 годин тому
Jason Abdou Mouabbi, MD, discusses considerations for the use of ribociclib vs abemaciclib in patients with HR-positive, HER2-negative breast cancer. Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses considerations for the use of ribociclib...
Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC
Переглядів 3212 годин тому
Jun Gong, MD, discusses the variety of PARP inhibitor-based frontline treatment regimens that are FDA approved for patients with mCRPC. Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, discusses the variety of frontline...
Dr Owonikoko on the Impact of the FDA Approval of Tarlatamab in ES-SCLC
Переглядів 11812 годин тому
Taofeek Owonikoko, MD, PhD, expands on the FDA approval of tarlatamab for patients with extensive-stage small cell lung cancer. Taofeek Owonikoko, MD, PhD, professor, medicine, Division of Hematology-Oncology, the University of Pittsburgh; chief, hematology, oncology the University of Pittsburgh Medical Center Hillman Cancer Center, expands on the FDA approval of tarlatamab-dlle (Imdelltra) for...
Dr Franses on the Feasibility of Co-Inhibiting Angiogenesis and PD-1 Pathways in HCC
Переглядів 2012 годин тому
Joseph Franses, MD, PhD, assistant professor, medicine, University of Chicago Medicine Comprehensive Cancer Center, debates whether targeting angiogenesis and the PD-1/PD-L1 pathway in hepatocellular carcinoma (HCC) is always a reliable approach. Results from the phase 3 IMbrave150 trial (NCT03434379) of atezolizumab (Tecentriq) and bevacizumab (Avastin) generated a lot of optimism for the co-i...
Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer
Переглядів 2612 годин тому
Lori Wirth, MD, associate professor, medicine, Harvard Medical School; medical director, Center for Head and Neck Cancers; Massachusetts General Hospital, discusses the significance of the June 2024 FDA full approval of selpercatinib (Retevmo) for adult and pediatric patients at least 2 years of age with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and ...
Dr Maakaron on Choosing Between Bispecific Antibodies and CAR T-Cell Therapy in DLBCL
Переглядів 4919 годин тому
Joseph Maakaron, MD, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in patients with DLBCL. Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School, discusses factors that influence his decision to use bispecific antibodies or CAR T-cell therapy in pati...
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma
Переглядів 3719 годин тому
Dr Mohty on the Real-World Efficacy of Elranatamab in R/R Multiple Myeloma
Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC
Переглядів 6919 годин тому
Dr Linscott on Urinary Cell-free Tumor DNA to Predict MRD in High-risk NMIBC
Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC
Переглядів 3519 годин тому
Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC
Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meeting
Переглядів 2419 годин тому
Dr O'Malley on Updates in Gynecologic Oncology at the 2024 ASCO Annual Meeting
Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC
Переглядів 7219 годин тому
Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC
Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma
Переглядів 919 годин тому
Dr Ignatz-Hoover on the Future of CAR T-Cell Therapy and Bispecific Antibodies in R/R Myeloma
Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer
Переглядів 2619 годин тому
Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
Переглядів 2019 годин тому
Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting
Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC
Переглядів 2221 годину тому
Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL
Переглядів 3721 годину тому
Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL
Dr McCarthy on Neutrophil-Mediated Immunosuppression in Multiple Myeloma
Переглядів 4321 годину тому
Dr McCarthy on Neutrophil-Mediated Immunosuppression in Multiple Myeloma
Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma
Переглядів 1821 годину тому
Dr Ip on the Impact of BCMA Alternative Splicing in Lymphoma and Multiple Myeloma
Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E-Mutant mCRC
Переглядів 3221 годину тому
Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E-Mutant mCRC
Dr Waks on Unmet Needs in Patients With HER2+ Breast Cancer
Переглядів 3621 годину тому
Dr Waks on Unmet Needs in Patients With HER2 Breast Cancer
Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma
Переглядів 39День тому
Dr Rifkin on the Evaluation of Prophylactic Tocilizumab Prior to Teclistamab in R/R Myeloma

КОМЕНТАРІ

  • @Johnconno
    @Johnconno 7 годин тому

    It's Horrific, I feel that I'm going insane.

  • @MosesEneye-dm2rq
    @MosesEneye-dm2rq 2 дні тому

    I really appreciate you making this video. My ex of 4 years cheated and gave me Herpes virus during our relationship and I was devastated. You've made me feel so much better #DrAdigba and seeing all these people share their stories !!!!!!!!😊❤

  • @nehaslife1113
    @nehaslife1113 4 дні тому

    BCR ABL 0.728 iska kya matlab hai??? CML Case Kam ho raha h jyada???. please.bataye??

  • @NicolasaEstelaMunozSoto-vc3lw

    En México ya está felicidades

  • @etawnperry5131
    @etawnperry5131 4 дні тому

    Thank you for helping save my life your a great doctor

  • @elizabethbeth9930
    @elizabethbeth9930 7 днів тому

    tamoxifen can cause breast cancer in the other breast !

  • @minismokeshop
    @minismokeshop 7 днів тому

    they make more money when your insurance pays for pills.

  • @Buy_YT_Views_227
    @Buy_YT_Views_227 8 днів тому

    Love it!

  • @alprincmalki
    @alprincmalki 8 днів тому

    I have itching time to time but not after hot shower what does that mean also my hemogolobin is normal but RBC is high

  • @user-tz8pf4pd4q
    @user-tz8pf4pd4q 9 днів тому

    Gaw Dayum this doctor is hawwwwt

  • @ceburockhead
    @ceburockhead 9 днів тому

    for acute gout or arthritis I take DEXA 1 mg for 3 days and its gone , im 65 yrs old male , wt 70 kg

  • @Ripleycat
    @Ripleycat 10 днів тому

    Anastrazole gave me insomnia and nausea. Tamoxifen gives me muscle and bone aches. 65 yr old, DCIS.

  • @TariqKhan-fv1bn
    @TariqKhan-fv1bn 10 днів тому

    I have this please help me

  • @kardste8114
    @kardste8114 12 днів тому

    How do u measure the lean muscle- and Why doesn’t every Cancer clinic do it??

  • @kardste8114
    @kardste8114 12 днів тому

    Is there a Standard of Care regarding Measuring and Tracking cancer cachexia?

  • @richle905
    @richle905 15 днів тому

    You have to spend a lot on your education to try to sound intelligent while saying something this stupid.

  • @khaliddurrani6432
    @khaliddurrani6432 16 днів тому

    BCLC has revised its guidelines whereby resection is an option for single tumor any size in child A patients without any evidence of portal hypertension. Eastern centres in Japan, Korea, China have their own criteria for resection that is not as restrictive as BCLC ( intermediate stage )

  • @trevordaviesable
    @trevordaviesable 19 днів тому

    My wife has leukaemia, I am looking for help via epigenetic possibilities . What possibilities are there particularly regarding diet but also in any avenue of possibility?

  • @annayoung6050
    @annayoung6050 20 днів тому

    I have been on herceptin for six years,I am ok with the treatment my question is just how long can I stay on this,as my ct scans are good I am 84years old

  • @beeftekproduction9380
    @beeftekproduction9380 21 день тому

    Normal ferritin but low hepcidin. Some days i get 2000+ extracystoles.

  • @Jobobasdhascy
    @Jobobasdhascy 22 дні тому

    Where do you get this in NZ

  • @shizuoka4232
    @shizuoka4232 23 дні тому

    Thank you

  • @SJ-wu9gx
    @SJ-wu9gx 23 дні тому

    Isnt regorafenib more effective in vegf cancers like peritoneum mets

  • @dehilakisuki8150
    @dehilakisuki8150 24 дні тому

    Everybody need to know that herbs is healthy, natural and powerful. My sister got cured of high risk Human Papillomavirus with a herbal medicine she bought and used from *DR MADIDA* on UA-cam. I recommend Dr Madida to everyone because he has really being helpful to me and our family at large🤗😊🎉.

  • @Nisha-kl8rl
    @Nisha-kl8rl 25 днів тому

    For anyone dealing with ITP, Planet Ayurveda's treatment is the best. Their holistic approach really works.

  • @Nisha-kl8rl
    @Nisha-kl8rl 25 днів тому

    Planet Ayurveda has the best treatment for ITP. My overall health has greatly improved since starting their regimen.

  • @Nisha-kl8rl
    @Nisha-kl8rl 25 днів тому

    Planet Ayurveda’s ITP treatment has given me the best results. I can’t recommend them enough.

  • @Rene-uz3eb
    @Rene-uz3eb 28 днів тому

    More than one chelator at same time works even better (edta, alb)

  • @user-fo2cc7xx4y
    @user-fo2cc7xx4y Місяць тому

    Why aren't oncologist giving mtor inhibitors for cancer? My mom is stage 4 . Will inhibting this slow tumor growth???😊

  • @thebeardedtuckfardo6168
    @thebeardedtuckfardo6168 Місяць тому

    i have this cancer, this doesnt make me feel like treatment is worth it, already did 18 weeks of it and been hospitalized for sepsis from cisplatin. but im a fighter so im going to fight it. just dont like hearing these kinda options.

  • @williamgriffin2132
    @williamgriffin2132 Місяць тому

    Ps I had all that had prostate cancer and they gave me Harmon treatment's

  • @mohinichavan7943
    @mohinichavan7943 Місяць тому

    Very good knowledge ❤

  • @Freakyneeks13
    @Freakyneeks13 Місяць тому

    Complicated disease.

  • @SampathDisanayaka-vp6wb
    @SampathDisanayaka-vp6wb Місяць тому

    IlovE uou

  • @adrianmedeea486
    @adrianmedeea486 Місяць тому

    For almost a year had Herpes and I was lonely and sad luckily I was directed to a very kind and Great DRALLENBEN who helped me cure my Herpes and today I am free from Herpes and healthy…… ☘️☘️☘️🍁🌸🍀

  • @alexanderrose-young1873
    @alexanderrose-young1873 Місяць тому

    What's the song in the background? 😊

  • @jamesscott1189
    @jamesscott1189 Місяць тому

    With prostate cancer, on Zytiga for 4 yrs. Lost sex drive in 6 mos. Energy down but stable. Quit working at 4 yrs 3 mos. Tried Erleada, no good. Now beginning chemo, age 81, male.

  • @q95oldies57
    @q95oldies57 Місяць тому

    Some rough side effects. I've been on it for 18 months. Aching muscles, joints, fatigue, minor hot flashes, just feeling weird.

  • @yamaha1675
    @yamaha1675 Місяць тому

    I have HH and have give phlebotomy for years. Now for a while my ferratin is 12 and all my iron levels are low. I feel absolutely terrible and am 49 years old. Is iron infusion safe? I wouldnt think so but not a doc!

  • @FayRaf-zq5om
    @FayRaf-zq5om Місяць тому

    never knew talking about cancer could be full of so much laughter and fun - i will try to remain in similar humorous mood at next chemo session!!

  • @PriscaLunga
    @PriscaLunga Місяць тому

    Hie my name is Prisca I was diagnosed with cancer 2021, lymphoma I did have my chemotherapy sections at Mpilo hospital in Zimbabwe but I have run out of funds to finish with my treatment,I have to do a CT scan so that they know how the medication is working, please I need ur help I don't work

  • @edithflores9476
    @edithflores9476 Місяць тому

    Y

  • @edithflores9476
    @edithflores9476 Місяць тому

    You are the best

  • @melaniepitt4295
    @melaniepitt4295 Місяць тому

    I have been on pembrolizumab and lenvatinib for nearly four months and have had to have dose reductions from 20mg to 8mg due to peripheral neuropathy which I contracted after chemotherapy two years ago, effecting my balance and strength plus extreme fatigue. I am concerned about only taking the minimum dose as from all I have researched online, 14mg is the lowest recommended. My doctors are concerned about my quality of life and asked me if I want to stop the treatment. As I can still look after myself, drive and on a good day, ride my horse, I will continue for now.

  • @Arateenteras
    @Arateenteras Місяць тому

    Interesting, though very little mention to the toxicity versus improvement of duration ,in months.I feel this should be a must in the conversation.Feels the way is treated it hasn’t lost completely humanitarian site ..versus “the improvement” I say as a cancer patient.Its despairing to listen, in spite of the interest and effort.Finally as “lab rat “ stage 4 that I am it would be nice that they contemplate this aspect as essential

  • @tammywade3649
    @tammywade3649 Місяць тому

    I take low dose aspirin, my white cells and platelets are high

  • @andersonsprairieviewfarm2552
    @andersonsprairieviewfarm2552 Місяць тому

    When I think of grains, I think of herbicides and pesticides and cancer.

  • @evefairy7740
    @evefairy7740 Місяць тому

    the damn thing is rising not from anal sex increase among hetero population, but because of damn haemorrhoid steroid creams and haem operations which reactivate HPV , anal dysplasia ....causing anal cancer! deception deception and deception- to make business from human health and lives

  • @belab9741
    @belab9741 Місяць тому

    Respected Sir im dijagnosed with GCT please can i contacted you on your email please

  • @yaminiayachitam
    @yaminiayachitam Місяць тому

    I think these doctors and scientists only care if the patient is alive, they don't care about the quality of life. Immunotherapy can deteriorate a patient's everyday life by worsening liver cirrhosis. They need to give full side effects and what are risk factors in complete detail before making any videos promoting immunotherapy